Enantiomeric Atropisomers Inhibit HCV Polymerase and/or HIV Matrix: Characterizing Hindered Bond Rotations and Target Selectivity

被引:42
作者
LaPlante, Steven R. [1 ]
Forgione, Pat
Boucher, Colette
Coulombe, Rene
Gillard, James
Hucke, Oliver
Jakalian, Araz
Joly, Marc-Andre
Kukolj, George
Lemke, Christopher
McCollum, Robert
Titolo, Steve
Beaulieu, Pierre L.
Stammers, Timothy
机构
[1] Boehringer Ingelheim Canada Ltd, Dept Chem, Laval, PQ H7S 2G5, Canada
关键词
NMR; CRYSTALLOGRAPHY; DISCOVERY; NS5B;
D O I
10.1021/jm401202a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
An anthranilic acid series of allosteric thumb pocket 2 HCV NS5B polymerase inhibitors exhibited hindered rotation along a covalent bond axis, and the existence of atropisomer chirality was confirmed by NMR, HPLC analysis on chiral supports, and computational studies. A thorough understanding of the concerted rotational properties and the influence exerted by substituents involved in this steric phenomenon was attained through biophysical studies on a series of truncated analogues. The racemization half-life of a compound within this series was determined to be 69 min, which was consistent with a class 2 atropisomer (intermediate conformational exchange). It was further found by X-ray crystallography that one enantiomer of a compound bound to the intended HCV NS5B polymerase target whereas the mirror image atropisomer was able to bind to an unrelated HIV matrix target. Analogues were then identified that selectively inhibited the former. These studies highlight that atropisomer chirality can lead to distinct entities with specific properties, and the phenomenon of atropisomerism in drug discovery should be evaluated and appropriately managed.
引用
收藏
页码:1944 / 1951
页数:8
相关论文
共 25 条
[1]  
Beaulieu PL, 2013, RSC DRUG DISCOV, V32, P248, DOI 10.1039/9781849737814-00248
[2]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[3]   Version 1.2 of the Crystallography and NMR system [J].
Brunger, Axel T. .
NATURE PROTOCOLS, 2007, 2 (11) :2728-2733
[4]   ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].
CHOO, QL ;
KUO, G ;
WEINER, AJ ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :359-362
[5]   The molecular configurations of polynuclear aromatic compounds. Part I. The resolution of gamma-6 : 6'-dinitro- and 4 : 6 : 4': 6'-tetranitro-diphenic acids into optically active components. [J].
Christie, GH ;
Kenner, J .
JOURNAL OF THE CHEMICAL SOCIETY, 1922, 121 :614-620
[6]   The Challenge of Atropisomerism in Drug Discovery [J].
Clayden, Jonathan ;
Moran, Wesley J. ;
Edwards, Paul J. ;
LaPlante, Steven R. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2009, 48 (35) :6398-6401
[7]  
Coulombe R., 2007, Viral polymerase inhibitors, Patent No. [WO 2007/087717, 2007087717]
[8]  
Fazal G., 2008, Viral polymerase inhibitors, Patent No. [2008019477, WO 2008/019477]
[9]   Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: Implications for membrane association and assembly [J].
Hill, CP ;
Worthylake, D ;
Bancroft, DP ;
Christensen, AM ;
Sundquist, WI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) :3099-3104
[10]   Development of therapeutics for chronic HCV infection [J].
Huang, Zhuhui ;
Murray, Michael G. ;
Secrist, John A., III .
ANTIVIRAL RESEARCH, 2006, 71 (2-3) :351-362